02
Beyond Blood Sugar: Why Cardiovascular Outcomes Should Drive Your Sitagliptin Conversation
For many Americans living with type 2 diabetes, A1C numbers dominate every clinical conversation — but emerging evidence suggests that heart health outcomes may be an equally critical factor when selecting a diabetes medication. This article examines what the clinical research says about sitagliptin and cardiovascular risk, and why US patients should be asking their cardiologists a different set of questions.